trending Market Intelligence /marketintelligence/en/news-insights/trending/vAQgfoyzB7cUgi04tX9kFw2 content esgSubNav
In This List

US FDA rejects Coherus biosimilar drug

Blog

Insight Weekly: Unease roils markets; US likely to slip into recession; firms' cash ratios fall

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch


US FDA rejects Coherus biosimilar drug

The U.S. Food and Drug Administration rejected Coherus Biosciences' application to manufacture CHS-1701, a biosimilar version of Amgen Inc.'s Neulasta.

Neulasta helps in the growth of new white blood cells, which protects against the risk of infection following chemotherapy.

In its complete response letter, the regulator asked Coherus to reanalyze samples from a subset of patients for immunogenecity and sought additional manufacturing related process information.

Immunogenecity refers to the ability of a drug or vaccine to stir a response from the patient's immune system.

Coherus is also developing CHS-1420, a biosimilar version of Abbvie Inc.'s arthritis drug Humira, which passed a bioequivalence study in March.